JPH0242508B2 - - Google Patents

Description

[Detailed description of the invention]

(Industrial Application Field) The present invention relates to a medical hard resin composition and a medical device. Specifically, the present invention relates to medical hard resin compositions and medical devices that have extremely high safety and do not cause hemolysis when they come into contact with blood. (Prior art) Currently, hard resin compositions are often used in place of glass, metal, etc. for various hard medical devices because they are lightweight, hard to break, inexpensive, and disposable. It is being By the way, it is very important for such medical devices to be inert to blood components. However, for example, if blood is collected into a conventionally used blood collection tube made of glass or hard resin and then stored in the blood collection tube for a long time, red blood cells become hemolyzed. Hemoglobin released due to hemolysis adversely affects various measurement results for clinical tests. Generally, a blood bag containing donated blood is attached with a blood collection tube containing the same blood as the blood in the blood bag to check compatibility with the patient's blood before transfusion. However, as the red blood cell concentrate approaches its expiry date of 21 days (in Japan), the blood in the blood collection tube becomes hemolyzed, which interferes with the test. This was a problem because it was stored away. Therefore, it is desired to develop a hard resin that does not cause hemolysis even when it comes into contact with blood for a long time. (Problems to be Solved by the Invention) Therefore, an object of the present invention is to provide a novel medical hard resin composition and a medical device.
Another object of the present invention is to provide a medical hard resin composition and a medical device that have excellent preservability for red blood cells. (Means for solving the problem) The above objects are achieved by adding the general formula () to the hard resin composition. (In the formula, R ¹ , R ² and R ³ each have 1 to 1 carbon atoms.
20 aliphatic hydrocarbon groups, and the sum of the carbon numbers of R ¹ , R ² and R ³ is 10 to 36. ) is achieved by a medical hard resin composition characterized by containing a triglyceride compound represented by: The present invention also provides a medical hard resin composition containing 0.5 to 5% by weight of a triglyceride compound represented by the general formula ().
The present invention further provides that R ¹ , R ² and R ³ in the general formula () are each an aliphatic hydrocarbon group having 1 to 10 carbon atoms, and the sum of the carbon numbers of R ¹ , R ² and R ³ is 10 to 10. 30, a medical hard resin composition. The present invention also provides the general formula ()
This refers to a medical hard resin composition in which at least one of R ¹ , R ² and R ³ has a branched structure. The present invention further provides a medical hard resin composition in which the triglyceride compound represented by the general formula () is glyceryl tri-2-ethylhexanoate. The present invention also provides a medical hard resin composition in which the hard resin is selected from the group consisting of acrylic resins, styrene resins, olefin resins, thermoplastic polyester resins, and polycarbonates. The present invention further provides a medical hard resin composition in which the acrylic resin is a homopolymer or copolymer of methyl methacrylate, methyl acrylate, ethyl methacrylate, ethyl acrylate, acrylonitrile, or methacrylonitrile. The present invention also provides that the styrenic resin is polystyrene, acrylonitrile-styrene copolymer, or acrylonitrile-butadiene-copolymer.
This shows a medical hard resin composition that is a styrene copolymer. The present invention also provides a medical hard resin composition in which the olefinic resin is polyethylene, polypropylene, or an ethylene-propylene copolymer. The present invention also provides a medical hard resin composition in which the thermoplastic polyester resin is polyethylene terephthalate or polybutylene terephthalate. The above objects also include the general formula () in the hard resin composition. (In the formula, R ¹ , R ² and R ³ each have 1 to 1 carbon atoms.
20 aliphatic hydrocarbon groups, and the sum of the carbon numbers of R ¹ , R ² and R ³ is 10 to 36. ) This is achieved by a medical device characterized in that it is substantially composed of a hard resin composition comprising a triglyceride compound represented by: The present invention also provides a medical device characterized in that it is substantially composed of a hard resin composition containing 0.5 to 5% by weight of a triglyceride compound represented by the general formula (). The present invention further provides that R ¹ , R ² and R ³ in the general formula () are each an aliphatic hydrocarbon group having 1 to 10 carbon atoms, and the sum of the carbon numbers of R ¹ , R ² and R ³ is 10 to 10. 30
This indicates a medical device. The present invention also provides a medical device in which at least one of R ¹ , R ² and R ³ in the general formula () has a branched structure. The present invention further provides a medical device in which the triglyceride compound represented by the general formula () is glyceryl tri-2-ethylhexanoate. The present invention also provides a medical device in which the hard resin is selected from the group consisting of acrylic resins, styrenic resins, olefinic resins, thermoplastic polyester resins, and polycarbonates. The invention further provides a medical device in which the acrylic resin is a homopolymer or copolymer of methyl methacrylate, methyl acrylate, ethyl methacrylate, ethyl acrylate, acrylonitrile or methacrylonitrile. The present invention also provides a medical device in which the styrenic resin is polystyrene, acrylonitrile-styrene copolymer, or acrylonitrile-butadiene-styrene copolymer. The present invention also provides a medical device in which the olefinic resin is polyethylene, polypropylene or ethylene-propylene copolymer. The present invention also provides a medical device in which the thermoplastic polyester resin is polyethylene terephthalate or polybutylene terephthalate. The present invention further provides a medical device characterized in that it is a blood collection tube. (Function) Therefore, the medical hard resin composition of the present invention:
In the hard resin composition, the general formula () (In the formula, R ¹ , R ² and R ³ each have 1 to 20 carbon atoms.
is an aliphatic hydrocarbon group, and R ¹ , R ² and
The sum of the carbon numbers of ^R3 is 10-36. ) The biggest feature is that it contains a triglyceride compound represented by: Surprisingly, this triglyceride compound represented by the general formula () has the same effect on preventing red blood cell hemolysis as di-2-ethylhexyl phthalate, and on the other hand, unlike di-2-ethylhexyl phthalate, it has no platelet aggregation ability. It was found that no adverse effects on blood components such as suppressive effects were observed. Furthermore, since the triglyceride compound represented by the general formula () has sufficient compatibility with various hard resins, if the triglyceride compound represented by the general formula () is blended, it can be used to preserve red blood cells when it comes into contact with blood. This means that a hard resin composition with good properties can be obtained. That is, when the hard resin composition comes into contact with blood, hemolysis of red blood cells is prevented by the action of the triglyceride compound represented by the general formula (), which is eluted from the resin composition and has an excellent protective effect on red blood cells. It becomes something. Therefore, the medical hard resin composition of the present invention is suitable as a material for medical devices, and molded products made using the material exhibit excellent processability, transparency, heat resistance, etc. Therefore, when used as a medical device, the effect can be fully demonstrated, and the effect is particularly remarkable in the case of a medical device such as a blood collection tube that comes into contact with body fluids such as blood. Hereinafter, the present invention will be explained in more detail based on embodiments. The hard resin used in the medical hard resin composition according to the present invention is one that is physiologically safe and has appropriate compatibility with the triglyceride compound represented by the general formula () as described below. For example, acrylic resin, styrene resin, olefin resin,
Examples include thermoplastic polyester resin and polycarbonate. In addition, in these hard resins, regardless of the type of hard resin, the melt flow index is 0.5 to 30 g/10 min, especially 5
~12g/10min is preferable. Examples of acrylic resins include alkyl (meth) such as methyl methacrylate, methyl acrylate, ethyl methacrylate, and ethyl acrylate.
There are homopolymers and copolymers of acrylate, acrylonitrile, methacrylonitrile, etc. Polystyrene resins include polystyrene, acrylonitrile-styrene copolymer, acrylonitrile-butadiene-styrene copolymer (ABS resin), etc., and olefin resins include medium to high density polyethylene, polypropylene, and ethylene-propylene copolymer. There are copolymers made of a combination of ethylene, propylene, and other α-olefins such as polymers, and thermoplastic polyester resins include polyethylene terephthalate, polybutylene terephthalate, and the like. Furthermore, the polycarbonate includes, in addition to bisphenol A type polycarbonate, those having various carbonate type structures. The hard resin used in the medical hard resin composition of the present invention is of course not limited to those exemplified above, but further hard resins include polymer blends of various resins. It is included. Therefore, the medical hard resin composition of the present invention contains the general formula () (In the formula, R ¹ , R ² and R ³ each have 1 to 1 carbon atoms.
20, preferably 1 to 14, most preferably 6 to 10 aliphatic hydrocarbon groups, and R ¹ , R ² and R ³
The sum of the carbon numbers is 10-36, preferably 10-30, most preferably 10-24. ) A triglyceride compound represented by: This general formula ()
The triglyceride compound represented by acts as a hemolysis inhibitor in the medical hard resin composition of the present invention. That is, when blood comes into contact with a product made of the medical hard resin composition of the present invention, the triglyceride compound represented by the general formula () eluted from the composition exerts a protective effect on red blood cells. It is. In the triglyceride compound represented by the general formula (), the number of carbon atoms in R ¹ , R ² and R ³ is 1 to 20.
This is because if the carbon number is outside the range of 1 to 20, the triglyceride compound and the hard resin will be incompatible, and it will be difficult to uniformly disperse the triglyceride compound into the contact blood due to elution and transfer from the resin composition. This is because the effect of preventing hemolysis cannot be expected. Furthermore, the same thing can be said when the sum of the carbon numbers of R ¹ , R ² and R ³ exceeds 36, whereas R ¹ , R ²
and when the sum of the carbon numbers of R ³ is less than 10,
There is a risk of causing hemolysis. Further, in the triglyceride compound represented by the general formula (), it is more preferable that at least one of R ¹ , R ² and R ³ has a branched structure in order to improve compatibility with the hard resin and the hemolysis prevention effect. Furthermore, in the triglyceride compound represented by the general formula (), aliphatic hydrocarbon groups R ¹ , R ² and R ³ do not necessarily have to be the same, and may be a combination of groups with different chain lengths. Furthermore, aliphatic hydrocarbon groups R ¹ , R ² and R ³ may be saturated aliphatic hydrocarbon groups or unsaturated aliphatic hydrocarbon groups. Specifically, the triglyceride compound represented by the general formula () includes glyceryl trivalerate (trivalerin), glyceryl triisovalerate, glyceryl tricaproate, glyceryl tricaprylate, glyceryl tri-2-ethylhexanoate, and glyceryl trivalerate. Tricaprate, glyceryl trilaurate (trilaurin), butanoyl divaleryl glycerin, butyryl diisovaleryl glycerin, valeryl dihexanoyl glycerin, hexanoyl dioctanoyl glycerin, hexanoyl bis(2-ethylhexanoyl)glycerin, octanoyl bis(2-ethylhexanoyl)glycerin, dioctanoyl 2- Ethylhexanoyl glycerin, 2-ethylhexanoyldidecanoyl glycerin, bis(2-ethylhexanoyl) decanoyl glycerin,
Examples include decanoyl dilauroyl glycerin and dilauroyl myristoyl glycerin, preferably glyceryl tri-2-ethylhexanoate and octanoyl bis(2-ethylhexanoyl)glycerin, most preferably glyceryl tri-2-ethylhexanoate. It is. The triglyceride compound represented by the above general formula () is contained in the medical hard resin composition of the present invention in an amount of 0.5 to 5% by weight, more preferably 2 to 5% by weight.
Contains 3% by weight. In other words, the blending amount of the triglyceride compound represented by the general formula () is 0.5
This is because if it is less than 5% by weight, the effect of suppressing hemolysis of red blood cells will not be sufficient, while if it exceeds 5% by weight, there is a possibility that the physical properties of the hard resin composition will be deteriorated. Furthermore, additives such as various stabilizers, lubricants, and antioxidants may be added to the medical hard resin composition of the present invention, if necessary. The medical hard resin composition of the present invention can be molded by any of the methods used for conventional hard resin compositions, such as injection molding and extrusion molding. The medical device of the present invention contains the general formula () in the hard resin composition. (In the formula, R ¹ , R ² and R ³ each have 1 to 1 carbon atoms.
20 aliphatic hydrocarbon groups, and the sum of the carbon numbers of R ¹ , R ² and R ³ is 10 to 36. ) is substantially composed of a hard resin composition containing a triglyceride compound represented by It has an excellent inhibitory effect on hemolysis. Therefore, the medical devices of the present invention preferably include those that come into contact with body fluids such as blood, concentrated red blood cells, or body fluid component solutions, such as blood collection tubes, and particularly those that come in contact for a long time. Preferred examples include, but are not limited to, blood collection bottles, test tubes, shears, various artificial organs such as artificial lungs and artificial kidneys, and housings for heat exchangers and the like. Next, one embodiment of the medical device according to the present invention will be described with reference to the drawings, taking a blood collection tube as an example. That is, FIG. 1 shows a tubular member 2 made of the medical hard resin composition of the present invention with one end closed and the other end open, and a punctureable butyl rubber member with the open end 3 of the tubular member 2 sealed. 1 shows a reduced pressure blood collection tube 1 which maintains an internal space 5 formed by a stopper member 4 in a reduced pressure state. The reduced pressure blood collection tube 1 having such a configuration is used in the following manner. That is, as shown in FIG. 2, one end is closed and the other end is open, and a blood collection needle 7 is screwed into the screw hole 6 of the closed end 10. Blood vessel holder 8
The reduced pressure blood collection tube 1 is inserted into the tube from the open end 3 side. This blood collection needle 7 consists of a blood vessel piercing part 7a and a plug puncturing part 7b, and a synthetic resin luer adapter 9.
It is packaged in Next, when the blood vessel piercing part 7a of the blood collection needle 7 is inserted under pressure into the closed end 10 of the blood collection tube holder 8, the plug puncture part 7b of the blood collection needle 7 punctures the luer adapter 9 and the plug member 4, as shown in FIG. Since the blood reaches the internal space 5 of the blood collection tube 1, the blood vessel and the internal space 5 communicate with each other, and due to the negative pressure in the internal space 5, the blood in the blood vessel flows into the internal space 5 of the blood collection tube 1 by an amount corresponding to the degree of vacuum. flows into. Next, blood sampling needle 7
Blood collection is completed by removing the blood vessel piercing portion 7b from the blood vessel, and the collected blood is stored in the blood collection tube 1 until it is subjected to a test. However, as mentioned above, the blood collection tube 1 is made of the medical hard resin composition of the present invention, and due to the action of the triglyceride compound represented by the general formula () that elutes and transfers from the composition into the blood, Since hemolysis of red blood cells is suppressed, even if the storage period is long, free hemoglobin will not have an adverse effect on various measurements for clinical tests, and accurate test values can be obtained. The above explanation uses blood collection tubes as an example, but other blood collection bottles, test tubes, shears, oxygenators,
Housings for various artificial organs such as artificial kidneys and heat exchangers are also suitably constructed from the above-mentioned hard resin composition. (Examples) Hereinafter, the present invention will be explained in more detail based on Examples. Example 1 Polyethylene terephthalate (UNIPET)
RT560, manufactured by Nippon Unipet Co., Ltd.) and 3 parts by weight of glyceryl tri-2-ethylhexanoate were mixed into pellets using a vented twin-screw extruder, and the pellets were injected. A 5 ml blood collection tube was prepared by molding. Approximately 3 ml of human EDTA-added blood was dispensed into the blood collection tube and stored at 4°C for 3 weeks. Then, the plasma hemoglobin concentration was
TMB method (Clinical Chemistry 23 749~
(1977) [Clin.Chem. 23 749-(1977)]). The results are shown in Table 1. Comparative Example 1 For comparison, a blood collection tube was prepared in the same manner as in Example 1 using pellets made only of polyethylene terephthalate (Unipet RT560, manufactured by Nippon Unipet Co., Ltd.), and the same experiment was conducted on this blood collection tube. Summer. The results are shown in Table 1. Example 2 Polystyrene (Estyrene G-12F, manufactured by Nippon Steel Chemical Co., Ltd.) was used instead of polyethylene terephthalate.
A blood collection tube was prepared in the same manner as in Example 1, except that a sample was used, and the same experiment was conducted on this blood collection tube. The results are shown in Table 1. Comparative Example 2 For comparison, polystyrene (Estyrene G
-12F, manufactured by Nippon Steel Chemical Co., Ltd.), a blood collection tube was prepared in the same manner as in Example 1,
A similar experiment was conducted using this blood collection tube. The results are shown in Table 1. Example 3 A blood collection tube was prepared in the same manner as in Example 1, except that polymethyl methacrylate (Parapet G, manufactured by Kyowa Gas Chemical Industry Co., Ltd.) was used instead of polyethylene terephthalate, and the same experiment was performed on this blood collection tube. I did it. The results are shown in Table 1. Comparative Example 3 For comparison, a blood collection tube was prepared in the same manner as in Example 1 using pellets made only of polymethyl methacrylate (Parapet G, manufactured by Kyowa Gas Chemical Industry Co., Ltd.). I conducted an experiment. The results are shown in Table 1. Example 4 A blood collection tube was prepared in the same manner as in Example 1, except that polyacrylonitrile (BAREX210, manufactured by Vestron Cop.) was used instead of polyethylene terephthalate, and the same experiment was conducted on this blood collection tube. Ta. The results are shown in Table 1. Comparative Example 4 For comparison, polyacrylonitrile (BAREX210, Vestron
A blood collection tube was prepared in the same manner as in Example 1 using pellets made only by A. Co., Ltd.), and the same experiment was conducted on this blood collection tube. The results are shown in Table 1.

[Table] Expressed as the average value of three data values.
As is clear from the results shown in Table 1, when the hard resin composition according to the present invention was used (Examples 1 to
In 4), when a hard resin composition that does not contain the triglyceride compound of the present invention and hardly dissolves into blood (Comparative Examples 1 to 4)
It was found that elution was suppressed to a low level compared to (Effects of the Invention) As described above, the present invention is a medical hard resin composition characterized in that a triglyceride compound represented by the general formula () is blended into a hard resin composition. Unlike glass and hard resin compositions, it has the effect of suppressing hemolysis of red blood cells, and has physical properties such as moldability, transparency, and heat resistance that are comparable to conventional hard resin compositions. It can be molded by any of the commonly used molding methods, such as injection molding and extrusion molding.
It is ideal as a material for medical equipment, especially medical equipment that comes into contact with blood, such as blood collection tubes. Furthermore, in the medical hard resin composition of the present invention, a triglyceride compound represented by the general formula () 0.5 to 5
% by weight, R ¹ , R ² and R ³ in the general formula () are each an aliphatic hydrocarbon group having 1 to 10 carbon atoms, and the number of carbon atoms of R ¹ , R ² and R ³ is The triglyceride compound represented by ^the general formula ⁽ ) has a branched structure, and more preferably, the triglyceride compound represented by ^the general formula () has a branched structure. When the hard resin is tri-2-ethylhexanoate, in addition, the hard resin is a hard vinyl chloride resin, an acrylic resin, a styrene resin,
selected from the group consisting of olefin resins, thermoplastic polyester resins, and polycarbonates; and acrylic resins that are homopolymers or copolymers of methyl methacrylate, methyl acrylate, ethyl methacrylate, ethyl acrylate, acrylonitrile, or methacrylonitrile. The styrene resin is polystyrene, acrylonitrile-styrene copolymer or acrylonitrile-butadiene-styrene copolymer, the olefin resin is polyethylene, polypropylene or ethylene-propylene copolymer, and the thermoplastic polyester resin is When it is polyethylene terephthalate or polybutylene terephthalate, the hemolysis suppressing effect and other physical properties will be even more excellent. The present invention also provides a medical device characterized in that it is substantially composed of a hard resin composition in which a triglyceride compound represented by the general formula () is blended into the hard resin composition. It has an excellent effect on hemolysis and suppresses hemolysis of red blood cells, and is extremely effective, especially when medical devices can come into contact with blood, such as blood collection tubes, without causing any risk of denaturing blood components. It can be said to be a medical device, and even when used as a blood collection tube, there is no need to worry about free hemoglobin interfering with various blood tests even after blood is stored for a long time. Further, in the medical device of the present invention, when the hard resin composition substantially constituting the medical device contains 0.5 to 5% by weight of a triglyceride compound represented by the general formula (), R ¹ in the general formula (), R ² and R ³ are each an aliphatic hydrocarbon group having 1 to 10 carbon atoms, and the sum of the carbon numbers of R ¹ , R ² and R ³ is 10 to 30;
Furthermore, R ¹ , R ² and
At least one of R ³ has a branched structure, more preferably when the triglyceride compound represented by the general formula () is glyceryl tri-2-ethylhexanoate, and in addition, the hard resin is a hard vinyl chloride compound. resins selected from the group consisting of acrylic resins, styrenic resins, olefinic resins, thermoplastic polyester resins and polycarbonates; It is a homopolymer or copolymer of lonitrile, the styrene resin is polystyrene, acrylonitrile-styrene copolymer, or acrylonitrile-butadiene-styrene copolymer, and the olefin resin is polyethylene, polypropylene, or ethylene-propylene copolymer. If the thermoplastic polyester resin is polyethylene terephthalate or polybutylene terephthalate,
It becomes a medical device that is superior in other respects such as hemolysis-inhibiting action, heat resistance, and transparency.

[Brief explanation of drawings]

FIG. 1 is a cross-sectional view showing an embodiment of the medical device of the present invention, and FIGS. 2 and 3 are cross-sectional views showing how the same embodiment is used. DESCRIPTION OF SYMBOLS 1... Decompression blood collection tube, 2... Tubular member, 4... Plug member, 5... Internal space, 6... Screw hole, 7... Blood collection needle, 8... Blood collection tube holder, 9... Luer adapter.

Claims (1)

[Claims] 1. In the hard resin composition, the general formula () (In the formula, R ¹ , R ² and R ³ each have 1 to 1 carbon atoms.
20 aliphatic hydrocarbon groups, and the sum of the carbon numbers of R ¹ , R ² and R ³ is 10 to 36. ) A medical hard resin composition containing a triglyceride compound represented by: 2. The medical hard resin composition according to claim 1, which contains 0.5 to 5% by weight of a triglyceride compound represented by the general formula (). 3 R ¹ , R ² and R ³ in the general formula () are each an aliphatic hydrocarbon group having 1 to 10 carbon atoms,
The medical hard resin composition according to claim 1 or 2, wherein the sum of the carbon numbers of R ¹ , R ² and R ³ is 10 to 30. 4. The medical hard resin composition according to any one of claims 1 to 3, wherein at least one of R ¹ , R ² and R ³ in the general formula () has a branched structure. 5. The medical hard resin composition according to any one of claims 1 to 4, wherein the triglyceride compound represented by the general formula () is glyceryl tri-2-ethylhexanoate. 6. According to any one of claims 1 to 5, the hard resin is selected from the group consisting of acrylic resin, styrene resin, olefin resin, thermoplastic polyester resin, and polycarbonate. Medical hard resin composition. 7 Acrylic resin is methyl methacrylate,
The medical hard resin composition according to claim 6, which is a homopolymer or copolymer of methyl acrylate, ethyl methacrylate, ethyl acrylate, acrylonitrile, or methacrylonitrile. 8. The medical hard resin composition according to claim 6, wherein the styrene resin is polystyrene, an acrylonitrile-styrene copolymer, or an acrylonitrile-butadiene-styrene copolymer. 9. The medical hard resin composition according to claim 6, wherein the olefin resin is polyethylene, polypropylene, or an ethylene-propylene copolymer. 10. The medical hard resin composition according to claim 6, wherein the thermoplastic polyester resin is polyethylene terephthalate or polybutylene terephthalate. 11 In the hard resin composition, the general formula () (In the formula, R ¹ , R ² and R ³ each have 1 to 1 carbon atoms.
20 aliphatic hydrocarbon groups, and the sum of the carbon numbers of R ¹ , R ² and R ³ is 10 to 36. ) A medical device characterized in that it is substantially composed of a hard resin composition containing a triglyceride compound represented by: 12. The medical device according to claim 11, which is substantially composed of a hard resin composition containing 0.5 to 5% by weight of a triglyceride compound represented by the general formula (). 13 R ¹ , R ² and R ³ in the general formula () are each an aliphatic hydrocarbon group having 1 to 10 carbon atoms, and the sum of the carbon numbers of R ¹ , R ² and R ³ is 10 to 30
The medical device according to claim 11 or 12. 14. The medical device according to any one of claims 11 to 13, wherein at least one of R ¹ , R ² and R ³ in general formula () has a branched structure. 15. The medical device according to any one of claims 11 to 14, wherein the triglyceride compound represented by the general formula () is glyceryl tri-2-ethylhexanoate. 16 Claims 11 to 1, wherein the hard resin is selected from the group consisting of acrylic resin, styrene resin, olefin resin, thermoplastic polyester resin, and polycarbonate.
Medical device according to any of Item 5. 17. The medical device according to claim 16, wherein the acrylic resin is a homopolymer or copolymer of methyl methacrylate, methyl acrylate, ethyl methacrylate, ethyl acrylate, acrylonitrile, or methacrylonitrile. 18. The medical device according to claim 16, wherein the styrene resin is polystyrene, an acrylonitrile-styrene copolymer, or an acrylonitrile-butadiene-styrene copolymer. 19. The medical device according to claim 16, wherein the olefin resin is polyethylene, polypropylene, or ethylene-propylene copolymer. 20. The medical device according to claim 16, wherein the thermoplastic polyester resin is polyethylene terephthalate or polybutylene terephthalate. 21. The medical device according to any one of claims 11 to 20, which is a blood collection tube.